ArticleEuropean journal of nuclear medicine and molecular imaging2013
Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best.
Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Association of Nuclear Medicine (EANM) celebrated its 25th Anniversary Congress in Milan under the chairmanship of Professor Emilio Bombardieri and the auspices of the Italian Society of Nuclear Medicine. As always, the Congress was a great success: more than 5,530 participants from 88 countries came from Europe and beyond. In spite of limited budgets, industry again made an important contribution: New innovative equipment and tracers demonstrating the latest technology and innovations were presented by 122 companies. This review is a brief summary of the major scientific contributions made in the fields of oncology, multimodality imaging, cardiovascular science, neurology and psychiatry, technological innovation and novel tracers, and in other clinical sciences as well as in radionuclide therapy, which all show promising and great innovations.
Indexed as
Identifiers
23917722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.